13F-HR filed by Pfizer Inc
Pfizer Inc filed this 13F-HR for the quarter ended 2025-06-30, filed 2025-08-11, with 21 holding rows worth $576,193,012.
- Accession
- 0000078003-25-000142
- Filer
- CIK 78003
- Filed
- 2025-08-11
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2025
A holdings report, 24 entries on the cover page, a total value of $576,193,012 stated on the cover page (in dollars after the unit check, H1), rows summing to $576,193,012 with VALUE read as dollars as filed, 13F file number 028-25239. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| BIONTECH SE SPONSORED ADS | 09075V102 | ADR | 3,658,361 | $389,505,696 | dollars as filed | |
| ORIC PHARMACEUTICALS INC | 68622P109 | COM | 5,376,344 | $54,569,892 | dollars as filed | |
| ARVINAS INC | 04335A105 | COM | 3,457,815 | $25,449,518 | dollars as filed | |
| ALLOGENE THERAPEUTICS INC | 019770106 | COM | 22,032,040 | $24,896,205 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 1,272,214 | $20,342,702 | dollars as filed | |
| WAVE LIFE SCIENCES LTD SHS | Y95308105 | Stock | 1,875,000 | $12,187,500 | dollars as filed | |
| PYXIS ONCOLOGY INC COMMON STOCK | 747324101 | Stock | 7,032,770 | $7,736,047 | dollars as filed | |
| CARDIFF ONCOLOGY INC | 14147L108 | COM | 2,411,575 | $7,596,461 | dollars as filed | |
| BIOHAVEN LTD | G1110E107 | COM | 505,645 | $7,134,651 | dollars as filed | |
| SPERO THERAPEUTICS INC | 84833T103 | COM | 2,362,348 | $6,850,809 | dollars as filed | |
| CARIBOU BIOSCIENCES INC COM | 142038108 | Stock | 4,690,431 | $5,909,943 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 349,406 | $4,664,570 | dollars as filed | |
| ZURA BIO LTD | G9TY5A101 | COMMON STOCK | 2,970,022 | $3,118,523 | dollars as filed | |
| ESSA PHARMA INC | 29668H708 | COM NEW | 1,675,000 | $2,847,500 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 953,834 | $1,106,447 | dollars as filed | |
| NEXTCURE INC | 65343E108 | COM | 157,646 | $870,206 | dollars as filed | |
| AN2 THERAPEUTICS INC | 037326105 | COM | 715,295 | $758,213 | dollars as filed | |
| Q32 BIO INC | 746964105 | Common Stock | 277,777 | $413,888 | dollars as filed | |
| BOLT BIOTHERAPEUTICS INC | 097702203 | COM NEW | 31,305 | $180,630 | dollars as filed | |
| GINKGO BIOWORKS HOLDINGS INC | 37611X209 | COMMON STOCK | 2,928 | $32,940 | dollars as filed | |
| SENSEONICS HLDGS INC | 81727U105 | COM | 43,426 | $20,671 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000078003-25-000142 | this filing | 2025-08-11 | acceptance time not in the bulk data set |